{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:51:48Z","timestamp":1782802308334,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,5,27]],"date-time":"2011-05-27T00:00:00Z","timestamp":1306454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Mifepristone (MF) has been largely used in reproductive medicine due to its capacity to modulate the progesterone receptor (PR). The study of MF has been expanded to the field of oncology; yet it remains unclear whether the expression of PR is required for MF to act as an anti-cancer agent. Our laboratory has shown that MF is a potent inhibitor of ovarian cancer cell growth. In this study we questioned whether the growth inhibitory properties of MF observed in ovarian cancer cells would translate to other cancers of reproductive and non-reproductive origin and, importantly, whether its efficacy is related to the expression of cognate PR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Dose-response experiments were conducted with cancer cell lines of the nervous system, breast, prostate, ovary, and bone. Cultures were exposed to vehicle or increasing concentrations of MF for 72 h and analysed for cell number and cell cycle traverse, and hypodiploid DNA content characteristic of apoptotic cell death. For all cell lines, expression of steroid hormone receptors upon treatment with vehicle or cytostatic doses of MF for 24 h was studied by Western blot, whereas the activity of the G1\/S regulatory protein Cdk2 in both treatment groups was monitored <jats:italic>in vitro<\/jats:italic> by the capacity of Cdk2 to phosphorylate histone H1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>MF growth inhibited all cancer cell lines regardless of tissue of origin and hormone responsiveness, and reduced the activity of Cdk2. Cancer cells in which MF induced G1 growth arrest were less susceptible to lethality in the presence of high concentrations of MF, when compared to cancer cells that did not accumulate in G1. While all cancer cell lines were growth inhibited by MF, only the breast cancer MCF-7 cells expressed cognate PR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Antiprogestin MF inhibits the growth of different cancer cell lines with a cytostatic effect at lower concentrations in association with a decline in the activity of the cell cycle regulatory protein Cdk2, and apoptotic lethality at higher doses in association with increased hypodiploid DNA content. Contrary to common opinion, growth inhibition of cancer cells by antiprogestin MF is not dependent upon expression of classical, nuclear PR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-11-207","type":"journal-article","created":{"date-parts":[[2011,5,27]],"date-time":"2011-05-27T18:24:01Z","timestamp":1306520641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression"],"prefix":"10.1186","volume":"11","author":[{"given":"Chelsea R","family":"Tieszen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia A","family":"Goyeneche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BreeAnn N","family":"Brandhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey T","family":"Ortbahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos M","family":"Telleria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,27]]},"reference":[{"issue":"14","key":"2703_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1517\/14656566.9.14.2459","volume":"9","author":"G Benagiano","year":"2008","unstructured":"Benagiano G, Bastianelli C, Farris M: Selective progesterone receptor modulators 1: use during pregnancy. Expert Opin Pharmacother. 2008, 9 (14): 2459-2472. 10.1517\/14656566.9.14.2459.","journal-title":"Expert Opin Pharmacother"},{"issue":"14","key":"2703_CR2","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1517\/14656566.9.14.2473","volume":"9","author":"G Benagiano","year":"2008","unstructured":"Benagiano G, Bastianelli C, Farris M: Selective progesterone receptor modulators 2: use in reproductive medicine. Expert Opin Pharmacother. 2008, 9 (14): 2473-2485. 10.1517\/14656566.9.14.2473.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"2703_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1517\/13543784.17.4.469","volume":"17","author":"C Moller","year":"2008","unstructured":"Moller C, Hoffmann J, Kirkland TA, Schwede W: Investigational developments for the treatment of progesterone-dependent diseases. Expert Opin Investig Drugs. 2008, 17 (4): 469-479. 10.1517\/13543784.17.4.469.","journal-title":"Expert Opin Investig Drugs"},{"issue":"14","key":"2703_CR4","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1517\/14656566.9.14.2487","volume":"9","author":"G Benagiano","year":"2008","unstructured":"Benagiano G, Bastianelli C, Farris M: Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin Pharmacother. 2008, 9 (14): 2487-2496. 10.1517\/14656566.9.14.2487.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"2703_CR5","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1210\/endo-116-6-2236","volume":"116","author":"KB Horwitz","year":"1985","unstructured":"Horwitz KB: The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells. Endocrinology. 1985, 116 (6): 2236-2245. 10.1210\/endo-116-6-2236.","journal-title":"Endocrinology"},{"issue":"12","key":"2703_CR6","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1054\/bjoc.2001.2167","volume":"85","author":"VC Lin","year":"2001","unstructured":"Lin VC, Aw SE, Ng EH, Tan MG: Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues. Br J Cancer. 2001, 85 (12): 1978-1986. 10.1054\/bjoc.2001.2167.","journal-title":"Br J Cancer"},{"issue":"2","key":"2703_CR7","first-page":"369","volume":"23","author":"Y Liang","year":"2003","unstructured":"Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV: Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol. 2003, 23 (2): 369-380.","journal-title":"Int J Oncol"},{"issue":"1","key":"2703_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/(SICI)1097-0045(20000401)43:1<31::AID-PROS5>3.0.CO;2-#","volume":"43","author":"MF El Etreby","year":"2000","unstructured":"El Etreby MF, Liang Y, Lewis RW: Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate. 2000, 43 (1): 31-42. 10.1002\/(SICI)1097-0045(20000401)43:1<31::AID-PROS5>3.0.CO;2-#.","journal-title":"Prostate"},{"issue":"4","key":"2703_CR9","first-page":"1047","volume":"29","author":"BT Moe","year":"2009","unstructured":"Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G: Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Research. 2009, 29 (4): 1047-1052.","journal-title":"Anticancer Research"},{"issue":"4","key":"2703_CR10","first-page":"1053","volume":"29","author":"BG Moe","year":"2009","unstructured":"Moe BG, Vereide AB, Orbo A, Sager G: High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis. Anticancer Research. 2009, 29 (4): 1053-1058.","journal-title":"Anticancer Research"},{"issue":"12","key":"2703_CR11","first-page":"4835","volume":"30","author":"R Fjelldal","year":"2010","unstructured":"Fjelldal R, Moe BT, Orbo A, Sager G: MCF-7 cell apoptosis and cell cycle arrest: non-genomic effects of progesterone and mifepristone (RU-486). Anticancer Research. 2010, 30 (12): 4835-4840.","journal-title":"Anticancer Research"},{"issue":"4","key":"2703_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/pros.2990260405","volume":"26","author":"MF Lin","year":"1995","unstructured":"Lin MF, Kawachi MH, Stallcup MR, Grunberg SM, Lin FF: Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate. 1995, 26 (4): 194-204. 10.1002\/pros.2990260405.","journal-title":"Prostate"},{"issue":"11","key":"2703_CR13","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1158\/1078-0432.CCR-07-0164","volume":"13","author":"AA Goyeneche","year":"2007","unstructured":"Goyeneche AA, Caron RW, Telleria CM: Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res. 2007, 13 (11): 3370-3379. 10.1158\/1078-0432.CCR-07-0164.","journal-title":"Clin Cancer Res"},{"key":"2703_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1475-2867-9-4","volume":"9","author":"EM Freeburg","year":"2009","unstructured":"Freeburg EM, Goyeneche AA, Seidel EE, Telleria CM: Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Cancer Cell Int. 2009, 9: 4-10.1186\/1475-2867-9-4.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"2703_CR15","first-page":"743","volume":"34","author":"EM Freeburg","year":"2009","unstructured":"Freeburg EM, Goyeneche AA, Telleria CM: Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol. 2009, 34 (3): 743-755.","journal-title":"Int J Oncol"},{"issue":"4","key":"2703_CR16","first-page":"743","volume":"15","author":"R Fauvet","year":"2006","unstructured":"Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G, Darai E: Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep. 2006, 15 (4): 743-748.","journal-title":"Oncol Rep"},{"issue":"5","key":"2703_CR17","first-page":"999","volume":"12","author":"FV Rose","year":"1996","unstructured":"Rose FV, Barnea ER: Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene. 1996, 12 (5): 999-1003.","journal-title":"Oncogene"},{"issue":"7","key":"2703_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1349-7006.2002.tb01323.x","volume":"93","author":"J Akahira","year":"2002","unstructured":"Akahira J, Suzuki T, Ito K, Kaneko C, Darnel AD, Moriya T, Okamura K, Yaegashi N, Sasano H: Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res. 2002, 93 (7): 807-815.","journal-title":"Jpn J Cancer Res"},{"issue":"3","key":"2703_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1210\/jcem-59-3-561","volume":"59","author":"TC Hamilton","year":"1984","unstructured":"Hamilton TC, Behrens BC, Louie KG, Ozols RF: Induction of progesterone receptor with 17 beta-estradiol in human ovarian cancer. J Clin Endocrinol Metab. 1984, 59 (3): 561-563. 10.1210\/jcem-59-3-561.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2703_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/gyno.2001.6221","volume":"82","author":"M Keith Bechtel","year":"2001","unstructured":"Keith Bechtel M, Bonavida B: Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol. 2001, 82 (1): 127-138. 10.1006\/gyno.2001.6221.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2703_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0960-0760(01)00081-4","volume":"78","author":"AC McDonnel","year":"2001","unstructured":"McDonnel AC, Murdoch WJ: High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane. J Steroid Biochem Mol Biol. 2001, 78 (2): 185-191. 10.1016\/S0960-0760(01)00081-4.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"2703_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12672-010-0023-9","volume":"1","author":"NJ Charles","year":"2010","unstructured":"Charles NJ, Thomas P, Lange CA: Expression of membrane progesterone receptors (mPR\/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events. Horm Canc. 2010, 1 (4): 167-176. 10.1007\/s12672-010-0023-9.","journal-title":"Horm Canc"},{"issue":"11","key":"2703_CR23","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1210\/en.2009-0730","volume":"150","author":"JJ Peluso","year":"2009","unstructured":"Peluso JJ, Gawkowska A, Liu X, Shioda T, Pru JK: Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology. 2009, 150 (11): 4846-4854. 10.1210\/en.2009-0730.","journal-title":"Endocrinology"},{"issue":"3","key":"2703_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","volume":"36","author":"K Vermeulen","year":"2003","unstructured":"Vermeulen K, Van Bockstaele DR, Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003, 36 (3): 131-149. 10.1046\/j.1365-2184.2003.00266.x.","journal-title":"Cell Prolif"},{"issue":"6","key":"2703_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0015-0282(97)00189-1","volume":"68","author":"DK Mahajan","year":"1997","unstructured":"Mahajan DK, London SN: Mifepristone (RU486): a review. Fertil Steril. 1997, 68 (6): 967-976. 10.1016\/S0015-0282(97)00189-1.","journal-title":"Fertil Steril"},{"issue":"6","key":"2703_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S1071-5576(98)00037-9","volume":"5","author":"CC Schneider","year":"1998","unstructured":"Schneider CC, Gibb RK, Taylor DD, Wan T, Gercel-Taylor C: Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig. 1998, 5 (6): 334-338. 10.1016\/S1071-5576(98)00037-9.","journal-title":"J Soc Gynecol Investig"},{"issue":"5","key":"2703_CR27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1210\/jc.77.5.1388","volume":"77","author":"J Pinski","year":"1993","unstructured":"Pinski J, Halmos G, Shirahige Y, Wittliff JL, Schally AV: Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486. J Clin Endocrinol Metab. 1993, 77 (5): 1388-1392. 10.1210\/jc.77.5.1388.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2703_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1227\/00006123-199009000-00008","volume":"27","author":"WH Lee","year":"1990","unstructured":"Lee WH: Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery. 1990, 27 (3): 389-395. 10.1227\/00006123-199009000-00008. discussion 396","journal-title":"Neurosurgery"},{"issue":"4","key":"2703_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/cmt.6.4.285.292","volume":"6","author":"M Wahab","year":"2003","unstructured":"Wahab M, Al-Azzawi F: Meningioma and hormonal influences. Climacteric. 2003, 6 (4): 285-292.","journal-title":"Climacteric"},{"issue":"8","key":"2703_CR30","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/07357900601062339","volume":"24","author":"SM Grunberg","year":"2006","unstructured":"Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R: Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006, 24 (8): 727-733. 10.1080\/07357900601062339.","journal-title":"Cancer Invest"},{"issue":"6","key":"2703_CR31","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.fertnstert.2005.05.056","volume":"84","author":"IM Spitz","year":"2005","unstructured":"Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R: Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005, 84 (6): 1719-1726. 10.1016\/j.fertnstert.2005.05.056.","journal-title":"Fertil Steril"},{"issue":"12","key":"2703_CR32","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1210\/en.2002-220369","volume":"143","author":"LN Petz","year":"2002","unstructured":"Petz LN, Ziegler YS, Loven MA, Nardulli AM: Estrogen receptor alpha and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology. 2002, 143 (12): 4583-4591. 10.1210\/en.2002-220369.","journal-title":"Endocrinology"},{"issue":"5","key":"2703_CR33","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1210\/endo-108-5-1703","volume":"108","author":"KB Horwitz","year":"1981","unstructured":"Horwitz KB, Aiginger P, Kuttenn F, McGuire WL: Nuclear estrogen receptor release from antiestrogen suppression: amplified induction of progesterone receptor in MCF-7 human breast cancer cells. Endocrinology. 1981, 108 (5): 1703-1709. 10.1210\/endo-108-5-1703.","journal-title":"Endocrinology"},{"issue":"3","key":"2703_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0960-0760(02)00027-4","volume":"80","author":"A Vienonen","year":"2002","unstructured":"Vienonen A, Syvala H, Miettinen S, Tuohimaa P, Ylikomi T: Expression of progesterone receptor isoforms A and B is differentially regulated by estrogen in different breast cancer cell lines. J Steroid Biochem Mol Biol. 2002, 80 (3): 307-313. 10.1016\/S0960-0760(02)00027-4.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"2703_CR35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1210\/jc.75.3.865","volume":"75","author":"M Thomas","year":"1992","unstructured":"Thomas M, Monet JD: Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab. 1992, 75 (3): 865-870. 10.1210\/jc.75.3.865.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2703_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1023\/A:1006078032287","volume":"51","author":"MF El Etreby","year":"1998","unstructured":"El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV: Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1998, 51 (2): 149-168. 10.1023\/A:1006078032287.","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"2703_CR37","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-03-0637","volume":"10","author":"VT Gaddy","year":"2004","unstructured":"Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV: Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res. 2004, 10 (15): 5215-5225. 10.1158\/1078-0432.CCR-03-0637.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2703_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/A:1006098124087","volume":"51","author":"F Darro","year":"1998","unstructured":"Darro F, Cahen P, Vianna A, Decaestecker C, Nogaret JM, Leblond B, Chaboteaux C, Ramos C, Petein M, Budel V, Schoofs A, Pourrias B, Kiss R: Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Breast Cancer Res Treat. 1998, 51 (1): 39-55. 10.1023\/A:1006098124087.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2703_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/(SICI)1097-0045(20000201)42:2<99::AID-PROS3>3.0.CO;2-I","volume":"42","author":"MF El Etreby","year":"2000","unstructured":"El Etreby MF, Liang Y, Johnson MH, Lewis RW: Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate. 2000, 42 (2): 99-106. 10.1002\/(SICI)1097-0045(20000201)42:2<99::AID-PROS3>3.0.CO;2-I.","journal-title":"Prostate"},{"issue":"4","key":"2703_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pros.1108","volume":"48","author":"H Bonkhoff","year":"2001","unstructured":"Bonkhoff H, Fixemer T, Hunsicker I, Remberger K: Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate. 2001, 48 (4): 285-291. 10.1002\/pros.1108.","journal-title":"Prostate"},{"issue":"5","key":"2703_CR41","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jnci\/94.5.384","volume":"94","author":"M Sasaki","year":"2002","unstructured":"Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S, Dahiya R: Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst. 2002, 94 (5): 384-390.","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"2703_CR42","doi-asserted-by":"publisher","first-page":"31136","DOI":"10.1074\/jbc.M305153200","volume":"278","author":"IU Agoulnik","year":"2003","unstructured":"Agoulnik IU, Krause WC, Bingman WE, Rahman HT, Amrikachi M, Ayala GE, Weigel NL: Repressors of androgen and progesterone receptor action. J Biol Chem. 2003, 278 (33): 31136-31148. 10.1074\/jbc.M305153200.","journal-title":"J Biol Chem"},{"issue":"7","key":"2703_CR43","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1128\/MCB.19.7.5036","volume":"19","author":"I Rogatsky","year":"1999","unstructured":"Rogatsky I, Hittelman AB, Pearce D, Garabedian MJ: Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids. Mol Cell Biol. 1999, 19 (7): 5036-5049.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2703_CR44","first-page":"1809","volume":"43","author":"JS Horoszewicz","year":"1983","unstructured":"Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res. 1983, 43 (4): 1809-1818.","journal-title":"Cancer Res"},{"issue":"17","key":"2703_CR45","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1016\/S0021-9258(19)43537-0","volume":"248","author":"SC Brooks","year":"1973","unstructured":"Brooks SC, Locke ER, Soule HD: Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem. 1973, 248 (17): 6251-6253.","journal-title":"J Biol Chem"},{"key":"2703_CR46","volume-title":"Invest New Drugs","author":"AA Goyeneche","year":"2011","unstructured":"Goyeneche AA, Seidel EE, Telleria CM: Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Invest New Drugs. 2011"},{"issue":"6","key":"2703_CR47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/1043-2760(91)90030-Q","volume":"2","author":"EE Baulieu","year":"1991","unstructured":"Baulieu EE: The antisteroid RU486: its cellular and molecular mode of action. Trends Endocrinol Metab. 1991, 2 (6): 233-239. 10.1016\/1043-2760(91)90030-Q.","journal-title":"Trends Endocrinol Metab"},{"issue":"6-7","key":"2703_CR48","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.steroids.2007.03.012","volume":"72","author":"S Zhang","year":"2007","unstructured":"Zhang S, Jonklaas J, Danielsen M: The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007, 72 (6-7): 600-608. 10.1016\/j.steroids.2007.03.012.","journal-title":"Steroids"},{"issue":"39","key":"2703_CR49","doi-asserted-by":"publisher","first-page":"27857","DOI":"10.1074\/jbc.274.39.27857","volume":"274","author":"RH Oakley","year":"1999","unstructured":"Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA: The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem. 1999, 274 (39): 27857-27866. 10.1074\/jbc.274.39.27857.","journal-title":"J Biol Chem"},{"issue":"7","key":"2703_CR50","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1210\/en.2009-1254","volume":"151","author":"Y Taniguchi","year":"2010","unstructured":"Taniguchi Y, Iwasaki Y, Tsugita M, Nishiyama M, Taguchi T, Okazaki M, Nakayama S, Kambayashi M, Hashimoto K, Terada Y: Glucocorticoid receptor-beta and receptor-gamma exert dominant negative effect on gene repression but not on gene induction. Endocrinology. 2010, 151 (7): 3204-3213. 10.1210\/en.2009-1254.","journal-title":"Endocrinology"},{"issue":"12","key":"2703_CR51","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1128\/MCB.23.12.4319-4330.2003","volume":"23","author":"MR Yudt","year":"2003","unstructured":"Yudt MR, Jewell CM, Bienstock RJ, Cidlowski JA: Molecular origins for the dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol. 2003, 23 (12): 4319-4330. 10.1128\/MCB.23.12.4319-4330.2003.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2703_CR52","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1128\/MCB.01439-06","volume":"27","author":"LJ Lewis-Tuffin","year":"2007","unstructured":"Lewis-Tuffin LJ, Jewell CM, Bienstock RJ, Collins JB, Cidlowski JA: Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Mol Cell Biol. 2007, 27 (6): 2266-2282. 10.1128\/MCB.01439-06.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2703_CR53","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.bbrc.2009.02.110","volume":"381","author":"T Kino","year":"2009","unstructured":"Kino T, Manoli I, Kelkar S, Wang Y, Su YA, Chrousos GP: Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity. Biochem Biophys Res Commun. 2009, 381 (4): 671-675. 10.1016\/j.bbrc.2009.02.110.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2703_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pharmthera.2008.09.006","volume":"121","author":"HJ Rohe","year":"2009","unstructured":"Rohe HJ, Ahmed IS, Twist KE, Craven RJ: PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther. 2009, 121 (1): 14-19. 10.1016\/j.pharmthera.2008.09.006.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2703_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/humupd\/dmn044","volume":"15","author":"B Gellersen","year":"2009","unstructured":"Gellersen B, Fernandes MS, Brosens JJ: Non-genomic progesterone actions in female reproduction. Hum Reprod Update. 2009, 15 (1): 119-138.","journal-title":"Hum Reprod Update"},{"issue":"1-2","key":"2703_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.steroids.2010.09.006","volume":"76","author":"GE Dressing","year":"2011","unstructured":"Dressing GE, Goldberg JE, Charles NJ, Schwertfeger KL, Lange CA: Membrane progesterone receptor expression in mammalian tissues: A review of regulation and physiological implications. Steroids. 2011, 76 (1-2): 11-17. 10.1016\/j.steroids.2010.09.006.","journal-title":"Steroids"},{"issue":"2","key":"2703_CR57","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1210\/en.2006-0974","volume":"148","author":"P Thomas","year":"2007","unstructured":"Thomas P, Pang Y, Dong J, Groenen P, Kelder J, de Vlieg J, Zhu Y, Tubbs C: Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins. Endocrinology. 2007, 148 (2): 705-718.","journal-title":"Endocrinology"},{"issue":"5","key":"2703_CR58","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1210\/jc.2007-2771","volume":"93","author":"JJ Peluso","year":"2008","unstructured":"Peluso JJ, Liu X, Saunders MM, Claffey KP, Phoenix K: Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab. 2008, 93 (5): 1592-1599. 10.1210\/jc.2007-2771.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2703_CR59","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.steroids.2008.05.003","volume":"73","author":"JL Smith","year":"2008","unstructured":"Smith JL, Kupchak BR, Garitaonandia I, Hoang LK, Maina AS, Regalla LM, Lyons TJ: Heterologous expression of human mPRalpha, mPRbeta and mPRgamma in yeast confirms their ability to function as membrane progesterone receptors. Steroids. 2008, 73 (11): 1160-1173. 10.1016\/j.steroids.2008.05.003.","journal-title":"Steroids"},{"issue":"5","key":"2703_CR60","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1172\/JCI117551","volume":"94","author":"S Parthasarathy","year":"1994","unstructured":"Parthasarathy S, Morales AJ, Murphy AA: Antioxidant: a new role for RU-486 and related compounds. J Clin Invest. 1994, 94 (5): 1990-1995. 10.1172\/JCI117551.","journal-title":"J Clin Invest"},{"issue":"5","key":"2703_CR61","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0015-0282(00)01606-X","volume":"74","author":"AA Murphy","year":"2000","unstructured":"Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S, Sidell N: RU486-induced growth inhibition of human endometrial cells. Fertil Steril. 2000, 74 (5): 1014-1019. 10.1016\/S0015-0282(00)01606-X.","journal-title":"Fertil Steril"},{"issue":"4","key":"2703_CR62","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-0897.1995.tb00949.x","volume":"34","author":"CP Roberts","year":"1995","unstructured":"Roberts CP, Parthasarathy S, Gulati R, Horowitz I, Murphy AA: Effect of RU-486 and related compounds on the proliferation of cultured macrophages. Am J Reprod Immunol. 1995, 34 (4): 248-256.","journal-title":"Am J Reprod Immunol"},{"issue":"2","key":"2703_CR63","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0304-3835(00)00378-5","volume":"154","author":"M Liberto","year":"2000","unstructured":"Liberto M, Cobrinik D: Growth factor-dependent induction of p21(CIP1) by the green tea polyphenol, epigallocatechin gallate. Cancer Letters. 2000, 154 (2): 151-161. 10.1016\/S0304-3835(00)00378-5.","journal-title":"Cancer Letters"},{"issue":"9","key":"2703_CR64","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/carcin\/20.9.1869","volume":"20","author":"M Liu","year":"1999","unstructured":"Liu M, Wikonkal NM, Brash DE: Induction of cyclin-dependent kinase inhibitors and G(1) prolongation by the chemopreventive agent N-acetylcysteine. Carcinogenesis. 1999, 20 (9): 1869-1872. 10.1093\/carcin\/20.9.1869.","journal-title":"Carcinogenesis"},{"issue":"2","key":"2703_CR65","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12020-010-9362-0","volume":"38","author":"N Dioufa","year":"2010","unstructured":"Dioufa N, Kassi E, Papavassiliou AG, Kiaris H: Atypical induction of the unfolded protein response by mifepristone. Endocrine. 2010, 38 (2): 167-173. 10.1007\/s12020-010-9362-0.","journal-title":"Endocrine"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-207\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:13:13Z","timestamp":1630613593000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,27]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2703"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-207","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,27]]},"assertion":[{"value":"15 January 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"207"}}